Chemosensitivity of conjunctival melanoma cell lines to target-specific chemotherapeutic agents.
OBJECTIVE
In conjunctival melanoma, local chemotherapy has been based so far on clinical evidence and limited to the therapy of melanoma in situ. Our aim was to define substances that may have the potential to add to therapeutic options in extended local growth and metastatic disease. Two conjunctival cell lines (CRMM-1 and CRMM-2) have been established from recurrent conjunctival melanoma. In this study, we examined the chemosensitivity of these cell lines to different cytotoxic substances.


METHODS
The cell lines CRMM-1 and CRMM-2 were exposed to chemotherapeutics for 24 h and the IC50 was generated. Sulforhodamin-B assays were used for quantification of in vitro efficacy. Time of exposure and escalating concentrations of the substances were adapted to the experimental setting.


RESULTS
Bortezomib, clusianone 502 (nemorosone), ranpirnase, and sorafenib were efficient in inhibiting the growth of conjunctival melanoma cell lines. The IC50 achieved concentrations below or around 10 μM for these substances.


CONCLUSIONS
Bortezomib, clusianone 502, ranpirnase, and sorafenib inhibited growth in conjunctival melanoma cell lines efficiently. The new substances may be a suitable alternative for local therapy. New therapeutic options with highly specific targeted agents for metastatic disease have to be evaluated in further experiments.
Department of Ophthalmology, University Hospital Essen, Hufelandstr. 55, 45122 Essen, Germany.
Henrike
H
Westekemper
Michael
M
Freistuehler
Norbert
N
Bornfeld
Klaus-Peter
KP
Steuhl
Max
M
Scheulen
Ralf A
RA
Hilger
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001577:Benzophenones / Q000627:therapeutic use; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D049109:Cell Proliferation / Q000187:drug effects; D003230:Conjunctival Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D009536:Niacinamide / Q000031:analogs & derivatives / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use; D011719:Pyrazines / Q000627:therapeutic use; D012260:Ribonucleases / Q000627:therapeutic use; D000077157:Sorafenib; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D001577:Benzophenones; D001897:Boronic Acids; D010671:Phenylurea Compounds; D011719:Pyrazines; C437463:nemorosone; D009536:Niacinamide; D000069286:Bortezomib; D000077157:Sorafenib; D012260:Ribonucleases; C058703:ranpirnase